UDENYCA has been fully acquired by Intas Pharma for $558 million, the business said in a press statement. A biosimilar to Pegfilgrastim or Neulasta is UDENYCA. It is used to treat recurring infections and other radiation treatment adverse effects in cancer patients.

In December 2024, California-based Coherus Life Sciences sold the biosimilar medication to Intas.

The purchase strengthens Intas Pharma's position as a world leader in pegfilgrastim and enables it to further develop its specialized business in important foreign markets, according to Binesh Chudgar, chairman and managing director of the company.

UDENYCA has been bought by Intas Pharmaceuticals, in association with its international companies that operate under the Accord brand.

According to a press release from the company, the acquisition of Accord BioPharma, Intas' U.S. specialty business, aims to reduce the incidence of infection, as evidenced by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer medications linked to a clinically significant incidence of febrile neutropenia.

Chrys Kokino, President, USA, Accord BioPharma, says the UDENYCA acquisition is a major milestone for the company because it expands their capabilities and boosts their market presence as they strive to innovate and grow in the biosimilar industry.